Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus

Las Vegas, NV, January 09, 2008 --(PR.com)-- Amphocil Successfully Launched In Greece.

Samaritan Pharmaceuticals Inc., a developer of innovative drugs, announced today it has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece.

Amphocil (amphotericin B cholesteryl sulfate), an injection, is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients.

Dr. Janet Greeson of Samaritan stated, "We are making great strides in making Samaritan a revenue company. The niche territories of Greece and Eastern Europe are often overlooked although together the territories account for 300 million people, so we see it as an opportunity. Getting an already approved U.S. or European drug launched in our targeted territories takes a special expertise and long term relationships. We are fortunate to have built relationships in Ireland through Pharmaplaz, Ireland and we are extremely fortunate to have Dr. Christos Dakas as our European Director, who has built a long list of credible relationships in Greece and Eastern Europe. We give Dr. Dakas and Eugene Boyle a lot of credit for their persistence in trying to make Samaritan self sustaining in the future.''

###